Creating AXL Inhibitors for Aggressive Diseases

Creating AXL Inhibitors for Aggressive Diseases

Healthcare Tech Outlook | Wednesday, January 30, 2019

BerGenBio is a clinical oncology company that advances selective AXL kinase inhibitors as a future key element of multiple cancer combination therapies. Blocking AXL activity is a new approach to preventing cancer survival and enhancing chemotherapy efficacy, targeted therapy, and immuno-oncology drugs. Bemcentinib (BGB324) is a potent, selective, and orally bioavailable inhibitor of AXL and the most advanced clinical trial selective inhibitor of AXL.

BerGenBio is developing a diversified pipeline of selective AXL inhibitors, including biologics and small molecules, through its strong leadership position in understanding the role of AXL and related kinase triggers in extremely unmet disease. The Phase II program of BerGenBio focuses on creating evidence that bemcentinib can reverse and prevent immune targeted and chemotherapy resistance and further position bemcentinib as a potential future linchpin of cancer therapy. BerGenBio also develops companion diagnostics in addition to its clinical trials to identify patients for whom bemcentinib therapy could lead to more significant results. It has been shown that enriching clinical trials for relevant groups of patients increases the probability of obtaining regulatory approval by three folds.

BerGenBio, a clinical-stage biopharmaceutical company focused on the development of a pipeline of first-class AXL kinase inhibitors to treat multiple cancer indications, announces at the 9th Annual Nordic Healthcare Conference in Oslo, Norway, that the company will present key results from its Phase II clinical program with selective AXL bemcentinib inhibitor.

In 2018, BerGenBio made substantial progress in establishing clinical proof of concept for the remarkable use of bemcentinib in cancers with high clinical needs and high market potential. The company has demonstrated that its oral selective AXL inhibitor is well tolerated as a monotherapy and in combination with immunotherapy, targeting, and chemotherapy. Moreover, the company has consistently demonstrated that efficacy scales with AXL biomarker expression lead to higher response rates in AXL biomarker with positive relapsed/refractory AML and MDS as monotherapy and non-small cell lung cancer in combination with the Keytruda blockbuster immunotherapy. This year, the company has achieved all its operational milestones and looks forward to launching a randomized Phase II program toward the end of H1 2019 based on key results obtained.

Weekly Brief